Autres langues Tarsus Pharmaceuticals, Inc.

Actions

TARS

US87650L1035

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 12/08/2026			Varia. 5j.	Varia. 1 janv.
70,02 ^USD	+0,80%		+14,24%	-14,49%

12/08	Tarsus Pharmaceuticals, Inc. : Oppenheimer optimiste sur le dossier	ZM
07/08	Tarsus Pharmaceuticals, Inc. : Mizuho Securities toujours à l'achat	ZM

Autres langues

06/08	Tarsus Pharmaceuticals, Inc. entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc. for approximately $800 million.
06/08	Tarsus Pharmaceuticals, Inc. Increased Net Sales Guidance for Full Year 2026
06/08	Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
06/08	Earnings Flash (TARS) Tarsus Pharmaceuticals, Inc. Reports Q2 Revenue $173.9M, vs. FactSet Est of $169.7M
06/08	Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
06/08	Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
06/08	Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
06/08	Deals of the day-Mergers and acquisitions
06/08	Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
15/07	RxSight Names Aziz Mottiwala as CEO
13/07	Tarsus Pharmaceuticals, Inc. Announces Management Changes, Effective July 13, 2026
13/07	Tarsus Pharmaceuticals Appoints Neera Clase as Interim Chief Commercial Officer
13/07	Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
08/07	Tarsus Pharmaceuticals Buys iRenix Medical
08/07	Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
08/07	Tarsus Pharmaceuticals, Inc. completed the acqusisition of iRenix Medical, Inc.
08/07	Tarsus Pharmaceuticals, Inc. agreed to acquire iRenix Medical, Inc for approximately $570 million.
01/07	Tarsus Pharmaceuticals Faces Medicare Copay Allegations From Culper Research; Shares Fall
28/05	Tarsus to Participate in Upcoming Investor Conferences
14/05	Tarsus and John Cena partner to raise awareness of Demodex blepharitis, a common eyelid disease affecting approximately 25 million Americans
14/05	Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
07/05	Tarsus to Participate in Upcoming Investor Conferences
07/05	Tarsus Pharmaceuticals : Reports First Quarter 2026 Financial Results and Recent Business Achievements
07/05	Tarsus Pharmaceuticals : First Quarter 2026 Earnings Presentation